Wednesday, October 14, 2026

Venture Capital & Investment Trends

3 articles

Baseten $1.5B Series F Leads June Surge in AI Inference Investment

Baseten $1.5B Series F Leads June Surge in AI Inference Investment

Baseten closed a $1.5B Series F round in June 2026, the largest in a cluster of AI inference funding events that also included Groq's $650M raise and Upscale AI's Series A extension bringing its total financing to $500M. Nvidia simultaneously acquihired Groq's founder and key team members. The capital surge signals that AI inference infrastructure is entering a capital-intensive scaling phase.

LM Salvado•
VC Capital Shifts From Crypto to AI as US Regulatory Stance Drives Innovation Offshore

VC Capital Shifts From Crypto to AI as US Regulatory Stance Drives Innovation Offshore

Venture capital is reallocating from cryptocurrency to artificial intelligence amid regulatory fragmentation, with crypto innovators increasingly geofencing the US market. Investor Tim Draper reports that El Salvador, Japan, Dubai and Abu Dhabi are capturing crypto deals as SEC enforcement pushes innovation abroad, while alternative investment platforms and government-backed schemes reshape VC infrastructure.

ViaNews Editorial Team (Finance)•
Venture Capital Shifts $716M from Crypto Holdings to AI Enterprise Software

Venture Capital Shifts $716M from Crypto Holdings to AI Enterprise Software

Institutional investors are rotating capital from cryptocurrency assets—which grew 16% year-over-year to 716 million owners—into AI-enabled enterprise automation and private equity infrastructure plays. Series B funding now concentrates on enterprise automation platforms like Ivo and Nomagic, while specialist VC funds including Outlast and Cogito Capital target AI infrastructure. This mirrors Aswath Damodaran's thesis that AI represents disruptive, not merely instrumental, technology.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com